GC Corp. bought $16.5M of Artiva Biotherapeutics (ARTV)
Executed May 11, disclosed May 28, 17 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (May 28), the stock returned +26.2% (delay-adjusted); from the execution session (May 11), -37.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
GC Corp. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 1 priced purchase filing, the average 21-session return was -37.8% from execution and +26.2% from disclosure (delay-adjusted; derived). The largest single filing was $16.5M of ARTV (1,432,291 sh across 2 lots, as filed), executed May 11.
Healthcare · Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for pa…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→